Pfizer (PFE) Scheduled to Post Quarterly Earnings on Wednesday

Pfizer (NYSE:PFE) is scheduled to be announcing its earnings results before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $0.57 per share for the quarter. Pfizer has set its FY24 guidance at $2.05-2.25 EPS.Investors interested in participating in the company’s conference call can do so using this link.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period last year, the company earned $1.14 earnings per share. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. On average, analysts expect Pfizer to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.32 on Wednesday. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer has a 1 year low of $25.23 and a 1 year high of $40.37. The business has a fifty day simple moving average of $27.07 and a 200 day simple moving average of $28.52. The firm has a market cap of $149.04 billion, a price-to-earnings ratio of 73.11, a P/E/G ratio of 1.17 and a beta of 0.61.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on PFE shares. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $36.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.